Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Inebilizumab Reduces Risk of NMOSD Attacks

Key clinical point: Inebilizumab reduces the risk of NMOSD attacks.

Major finding: Compared with placebo, inebilizumab reduces the risk of an attack by 73%.

Study details: A randomized, controlled study of 231 patients with NMOSD.

Disclosures: This study was funded by Viela Bio and MedImmune.

Citation:

Cree B et al. AAN 2019. Abstract Plen02.001.